{
  "nctId": "NCT02964741",
  "briefTitle": "Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)",
  "officialTitle": "Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)",
  "protocolDocument": {
    "nctId": "NCT02964741",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-12-12",
    "uploadDate": "2022-05-13T14:13",
    "size": 9555616,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02964741/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "TRIPLE",
  "enrollmentInfo": {
    "enrollmentCount": 44,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-02-22",
    "completionDate": "2021-08-01",
    "primaryCompletionDate": "2021-06-01",
    "firstSubmitDate": "2016-10-07",
    "firstPostDate": "2016-11-16"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Episodic migraine (ICHD-3-beta) for at least 6 months, with at least one attack per month and less than 15 attacks per month\n* No intake of opiate medication for the past six months\n* No overuse of analgesic medication, defined as regular intake on ≥15 days per month for more than 3 months\n* Willing to limit the introduction of new treatments for headache management\n\nExclusion Criteria:\n\n* Presence of any other systemic or chronic pain disorder\n* History or current evidence of a psychotic disorder (e.g. schizophrenia) or substance abuse; bipolar or severe major depression, as evidenced by Beck Depression score of ≥ 30\n* History of neurological disorder (e.g. epilepsy, stroke, neuropathy, neuropathic pain)\n* Prior use of tDCS\n* Current use of opioid pain medications",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Days With Moderate-to-severe Headache",
        "description": "Moderate to severe headache is defined by the pain over 3 in an Numeric Rating Scale (NRS) ranging from 0 to 10 between end of treatment and one month follow-up.",
        "timeFrame": "End of treatment - over 1 month follow-up"
      },
      {
        "measure": "Responder Rate",
        "description": "Number of participants who showed a 50% reduction of days with moderate-to-severe headache compared to baseline.",
        "timeFrame": "End of treatment - over 1 month follow-up"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Pain Intensity Level Measured by the Visual Analog Scale in Migraineurs (Active or Sham)",
        "description": "Visual Analog Scale measures pain on a 0 to 10 scale, where 0 is \"no pain\" and 10 is \"worst possible pain\"",
        "timeFrame": "Approximately 45 days (Screening Visit [Original Baseline] to Follow Up #2 [28-days post-HD-tDCS treatment])"
      },
      {
        "measure": "Moderate to Severe Headache",
        "description": "Percentage of participants having moderate-to-severe headache between end of treatment and one month follow-up.\n\nDefined as a response greater than 3 on the (0-10) NRS scale",
        "timeFrame": "End of treatment - over 1 month follow-up"
      },
      {
        "measure": "Use of Rescue Medication",
        "description": "Percentage of participants who used rescue medication between end of treatment and one month follow-up",
        "timeFrame": "End of treatment - over 1 month follow-up"
      },
      {
        "measure": "Change in Mu-opioid Receptor Non-displaceable Binding Potential (BPND) in the Brains of Migraineurs During Sustained Thermal Pain Threshold Stress Challenge Subsequent to Treatment by HD-tDCS (Active or Sham).",
        "description": "Mu-opioid receptor BPND at PET #2 will be subtracted from mu-opioid receptor BPND at PET #1.\n\nPET #1 occurs during the week before HD-tDCS treatment begins. PET #2 occurs during the week after the final HD-tDCS treatment is completed.",
        "timeFrame": "Time between PET #1 and PET #2 is typically 21 days (minimum 17 days; maximum 42 days)."
      },
      {
        "measure": "Change in Mu-opioid Receptor Non-displaceable Binding Potential (BPND) in the Brains of Migraineurs at Rest Subsequent to Treatment by HD-tDCS (Active or Sham).",
        "description": "Mu-opioid receptor BPND at PET #2 will be subtracted from mu-opioid receptor BPND at PET #1.\n\nPET #1 occurs during the week before HD-tDCS treatment begins. PET #2 occurs during the week after the final HD-tDCS treatment is completed.",
        "timeFrame": "Time between PET #1 and PET #2 is typically 21 days (minimum 17 days; maximum 42 days)."
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 7
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 74,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:54.928Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}